MMP-9 expression in vascular endothelial cells is redox sensitive, and the oxidative stress secondary to hyperglycemia provide a rationale to use antioxidants to suppress MMP-9 expression
Therefore, we are proposing that, in addition to meeting other criteria, a hospital, if it is to qualify for initial RRC status for cost reporting periods beginning on or after October 1, 2023, must have, as the number of discharges for its cost reporting period that began during FY 2021, at least 5,000 (3,000 for an osteopathic hospital)
J Proteome Res 2013
Disclosures: Farzaneh Tamnanloo: Nothing to Disclose, Quang Toan Pham: Nothing to Disclose, Marie-Agns MCallum: Nothing to Disclose, Denis Cyr: Nothing to Disclose, Paula Waters: Nothing to Disclose, Emilie Beaulieu: Nothing to Disclose, Yannick Doyon: Nothing to Disclose, Ugur Halac: Nothing to Disclose, Claudia Raggi: Nothing to Disclose, Massimiliano Paganelli: Morphocell Technologies: Executive role 2500 THE RELATIONSHIP BETWEEN SERUM BILE ACIDS AND EVENT-FREE SURVIVAL FOLLOWING THE USE OF MARALIXIBAT FOR PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS: DATA FROM MARCH/MARCH-ON Richard Thompson 1 Lorenzo D'Antiga 2 Simon Horslen 3 Douglas Mogul 4 Tiago Nunes 4 Will Garner 4 Pamela Vig 4 Alexander Miethke 5 , 1 King's College London, United Kingdom, 2 Papa Giovanni XXIII, Bergamo, Italy, 3 UPMC Children's Hospital of Pittsburgh, Pennsylvania, 4 Mirum Pharmaceuticals, Inc., Foster City, California, 5 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio Background: Maralixibat, an inhibitor of the ileal bile acid transporter, is approved in the US for treatment of cholestatic pruritus in individuals 3 months with Alagille Syndrome (ALGS) and 5 years with Progressive Familial Intrahepatic Cholestasis (PFIC)
